Greater B Cell Diversity
Discover Thousands of Hits in Days, Not Months
Plasma B discovery on the Beacon platform enables automated, direct screening of B cells immediately after organ harvest and cell purification. B cells can be screened from multiple organs (spleen, bone marrow, lymph nodes) and cultured for multiple days in specialized media to enable repeated screens from a single cell sample.
Rapid Screening of the B Cell Repertoire
Plasma B Discovery on the Beacon Platform Enables Rapid Screening of the B Cell Repertoire Without Time-Consuming and Inefficient Hybridoma Fusion.
Link Sequence with Function in Just Two Days
Every antibody sequence can be mapped directly to a known antibody function. Sequence relationships identify individual mutations that confer antigen specificity, cross-reactivity, and function.
Down-Select Lead Candidates Earlier
The beacon enables downselection of lead candidates through multiple assays for antigen specificity and function. Nanopen™ chambers enable rapid, precise and highly sensitive assays.
With a NanoPen™ volume of only 250 picoliters, reactions are fast and precise. Assays complete in less than 1 hour, and chips can then be reset to enable the next assay to begin. Better characterization upfront reduces the expense of having to sequence or clone irrelevant non-functional hits.
LIGAND BLOCKING ASSAY
ANTIGEN SPECIFIC BEAD ASSAY
Plasma B Cell Screening
OUR OPTOSELECT™ CHIPS CAN SCREEN THOUSANDS OF PLASMA B CELLS AT THE SAME TIME.
With the Beacon plasma B cell workflow, everything you need to connect antibody function to gene sequence at the single-cell level is available. Increase your chances of finding rare functional antibodies (e.g., 0.01% of the plasma B cell repertoire).